Assessing Pleiotropic Effects of a Mixed-Mode Perpetrator Drug, Rifampicin, by Multiple Endogenous Biomarkers in Dogs
Drug Metabolism and Disposition · 2024
DOI: 10.1124/dmd.123.001564 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2024. Verfasst von Renmeng Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Drug Metabolism, Gilead Sciences Inc., Foster City, California. Hauptthemen laut MEDLINE: Rifampin, Cytochrome P-450 CYP3A. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Drug Metabolism, Gilead Sciences Inc., Foster City, California.
- Drug Metabolism, Gilead Sciences Inc., Foster City, California yurong.lai@gilead.com.
ORCID-Profile: Yurong Lai
Zitieren
APA
Liu, R., Ma, B., Mok, M. M., Murray, B. P., Subramanian, R., & Lai, Y. (2024). Assessing Pleiotropic Effects of a Mixed-Mode Perpetrator Drug, Rifampicin, by Multiple Endogenous Biomarkers in Dogs. Drug Metabolism and Disposition. https://doi.org/10.1124/dmd.123.001564
Vancouver
Liu R, Ma B, Mok MM, Murray BP, Subramanian R, Lai Y. Assessing Pleiotropic Effects of a Mixed-Mode Perpetrator Drug, Rifampicin, by Multiple Endogenous Biomarkers in Dogs. Drug Metabolism and Disposition. 2024. doi:10.1124/dmd.123.001564
BibTeX
@article{Liu2024,
author = {Liu, Renmeng and Ma, Bin and Mok, Marilyn M and Murray, Bernard P and Subramanian, Raju and Lai, Yurong},
title = {Assessing Pleiotropic Effects of a Mixed-Mode Perpetrator Drug, Rifampicin, by Multiple Endogenous Biomarkers in Dogs},
journal = {Drug Metabolism and Disposition},
year = {2024},
doi = {10.1124/dmd.123.001564}
}
EUVIMED